Lipiodol as an Imaging Biomarker of Tumor Necrosis After Transcatheter Chemoembolization Therapy in Patients With Primary and Metastatic Liver Cancer

Trial Profile

Lipiodol as an Imaging Biomarker of Tumor Necrosis After Transcatheter Chemoembolization Therapy in Patients With Primary and Metastatic Liver Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Ethiodized oil (Primary)
  • Indications Liver cancer
  • Focus Biomarker; Diagnostic use
  • Most Recent Events

    • 26 Feb 2018 Planned End Date changed from 1 Oct 2017 to 1 Mar 2019.
    • 26 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2018.
    • 21 Apr 2017 The primary end point has been changed from Measuring Lipiodol deposition in tumor to Tumor response by Response Evaluation Criteria in Solid Tumors (RECIST).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top